An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma

Proteasome inhibition represents one of the more important therapeutic targets in the treatment of multiple myeloma (MM), since by suppressing nuclear factor-κB activity, which promotes myelomagenesis, it makes plasma cells susceptible to proapoptotic signals. Bortezomib, the first proteasome inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Offidani, Massimo, Corvatta, Laura, Caraffa, Patrizia, Gentili, Silvia, Maracci, Laura, Leoni, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189713/
https://www.ncbi.nlm.nih.gov/pubmed/25302026
http://dx.doi.org/10.2147/OTT.S49187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189713/
https://www.ncbi.nlm.nih.gov/pubmed/25302026
http://dx.doi.org/10.2147/OTT.S49187

Ejemplares similares